glofitamab,tocilizumab,obinutuzumab
roche
['fil,veral,12', 'glofitamab', 'nct03075696', 'nhl', 'lymsm', 'obinu', 'lymphoma', 'dlbcl']
congress | #ash22 discussed use of glofitamab in pts with r/r lbcl. 35.4% of pts achieved cr. 79% of pts in cr at eot remained in cr at 2 years. one pt experienced progression at 12 month follow up post-eot.
#lymsm #medicalcongress #hematology 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm